Head and Neck Squamous Cell Carcinoma

View All

pharma-news-immutep-pfizer-novo-nordisk-arcutis
Immutep’ First-Line Treatment Positive Outcomes; Pfizer’s Once-Daily Oral GLP-1 Agonist Danuglipron; FDA Issues Complete Response Letter to Novo Nordisk; Arcutis’ ZORYVE® Cream 0.15% FDA Approval; NICE Recommends Ebglyss For Moderate To Severe Atopic Dermatitis

Immutep Announces Promising Outcomes for First-Line Treatment in PD-L1 Negative Head and Neck Squamous Cell Carcinoma Patients Immutep Limited announced positive results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial, evaluating eftilagimod alfa (efti) combined with MSD’s anti-PD-1 therapy KEYTR...

Find More

Head and Neck Cancers Market
Navigating Through the Treatment Market Landscape of Head and Neck Cancers

Head and neck cancer account for about 4% of all cancers in the United States. According to GloboCan, the HNSCC incidence in the US in 2020 was estimated to be 63,520 cases. As per estimates, it was observed that HNSCC is slightly more common in men than in women. The research and development and advent of advanced...

Find More

Delveinsight
Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016

DelveInsight, the leading market research and consulting company has added new report  Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clien...

Find More